GLYCOPHOS

This brand name is authorized in Austria, Brazil, Cyprus, Estonia, Spain, Finland, Hong Kong, Lithuania, New Zealand, Poland, Romania, Singapore

Active ingredients

The drug GLYCOPHOS contains one active pharmaceutical ingredient (API):

1 Sodium glycerophosphate pentahydrate anhydrous UNII YP1H63LJ2K - SODIUM GLYCEROPHOSPHATE ANHYDROUS

Read about Sodium glycerophosphate

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B05XA14	Sodium glycerophosphate	B Blood and blood forming organs → B05 Blood substitutes and perfusion solutions → B05X I.V. solution additives → B05XA Electrolyte solutions
Discover more medicines within B05XA14

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 509503901151411, 509520010027107, 509520010027207
Country: EE	Ravimiamet	Identifier(s): 1126875, 1887688
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 64328
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 054071, 535146
Country: HK	Department of Health Drug Office	Identifier(s): 51002
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1011187, 1086896
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 11292
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100111506, 100255116, 100294783, 100427043, 100468574
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W42748002, W42748003
Country: SG	Health Sciences Authority	Identifier(s): 11858P